Introduction to ART – October 2019
13 December 2019. Related: Supplements.
2019
UK Guide to PrEP – November 2019
13 December 2019. Related: Supplements, HIV prevention and transmission.
i-Base 2019 appeal: we need your help….
13 December 2019. Related: Editorial.
17th European AIDS Conference (EACS 2019)
13 December 2019. Related: Conference reports.
Capsid inhibitor GS-6207 (lenacapavir): potential for 6 monthly dosing for MDR HIV
13 December 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir/lamivudine as dual ART
13 December 2019. Related: Conference reports, Antiretrovirals.
Weight changes with doravirine-based first line therapy
13 December 2019. Related: Conference reports, Antiretrovirals, Side effects.
Bone and renal changes in the ADVANCE trial
13 December 2019. Related: Conference reports.
10th International Workshop on HIV and Ageing
13 December 2019. Related: Conference reports, Ageing and life expectancy.
Impact of isolation and loneliness on older people living with HIV
13 December 2019. Related: Conference reports, Ageing and life expectancy.
Doravirine approved by NHS England as single NNRTI and as part of FDC with 3TC/TDF
13 December 2019. Related: Antiretrovirals.
Fostemsavir submitted to US FDA for multidrug resistant HIV
13 December 2019. Related: Antiretrovirals.
Paediatric dispersible formulation of dolutegravir submitted to EMA and FDA
13 December 2019. Related: Antiretrovirals.
Tesamorelin for NAFLD in people living with HIV
13 December 2019. Related: Lipodystrophy and metabolic complications, Hepatitis coinfection.
13 December 2019 vol 20 no 14
13 December 2019. Related: PDFs.
HTB 13 December 2019 online
13 December 2019. Related: Editorial.
Where is cell and gene therapy in an HIV cure?
15 November 2019. Related: Cure-related research.
HTB 15 November 2019 online
15 November 2019. Related: Editorial.
17th European AIDS Conference (EACS 2019)
15 November 2019. Related: Conference reports.
EACS launch major update to European Treatment Guidelines (November 2019)
15 November 2019. Related: Conference reports, Guidelines.
Weight gain and metabolic syndrome with dolutegravir and TAF: results from the ADVANCE trial
15 November 2019. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
10th International Workshop on HIV and Ageing
15 November 2019. Related: Conference reports, Ageing and life expectancy.
Frailty in HIV care and the importance of lifestyle changes
15 November 2019. Related: Conference reports, Ageing and life expectancy.
Research into use of medicinal cannabis in HIV management
15 November 2019. Related: Conference reports, Ageing and life expectancy.
Vaping can help HIV positive smokers who are not motivated to quit cigarettes
15 November 2019. Related: Conference reports, Coinfections and complications, Cancer and HIV, Ageing and life expectancy.
Ibalizumab approved in the EU
15 November 2019. Related: Antiretrovirals.
US government claims patent infringement by Gilead Sciences over use of F/TAF and FTC/TDF as PrEP
15 November 2019. Related: Treatment access, HIV prevention and transmission.
Distinguishing potential mechanisms of HIV persistence
15 November 2019. Related: Cure-related research.
Case report from the first clinical trial of CRISPR-edited stem cells in people with HIV and cancers
15 November 2019. Related: Cure-related research.
DR-TB drugs under the microscope: five urgent actions to improve DR-TB treatment (6th edition)
15 November 2019. Related: TB coinfection.
15 November 2019 vol 20 no 13
15 November 2019. Related: PDFs.
HTB 18 October 2019 online
18 October 2019. Related: Editorial.
IDWeek (2019), 2–6 October 2019, Washington DC
18 October 2019. Related: Conference reports.
HIV suppression and safety with ibalizumab at 48 weeks in expanded access
18 October 2019. Related: Conference reports, Antiretrovirals.
Oral cabotegravir and rilpivirine is durable for 5.5 years in LATTE study
18 October 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir plus rilpivirine had good virologic, safety record in clinics before single tablet available
18 October 2019. Related: Conference reports, Antiretrovirals.
Switching from TDF to TAF linked to higher BMI and cardio risk
18 October 2019. Related: Conference reports, Antiretrovirals, Side effects.
Possible higher diabetes risk with raltegravir or PIs than NNRTIs
18 October 2019. Related: Conference reports, Antiretrovirals, Side effects.
Fostemsavir interaction study flags strong CYP3A inducers, statins, oral contraceptives
18 October 2019. Related: Conference reports, PK and drug interactions.
Over half of mostly black US HIV group has NAFLD – and many have NASH
18 October 2019. Related: Conference reports, Lipodystrophy and metabolic complications.
People taking more medications and women have higher fall risk in older HIV group
18 October 2019. Related: Conference reports, Coinfections and complications, Ageing and life expectancy.
No link between raltegravir and adverse birth outcomes in analysis in 2550 women
18 October 2019. Related: Conference reports, Pregnancy.
PrEP linked to lower HIV incidence in US, independent of TasP
18 October 2019. Related: Conference reports, HIV prevention and transmission.
Dual dolutegravir/lamivudine submitted to US FDA as switch option
18 October 2019. Related: Antiretrovirals.
UK contributes £1.4 billion towards Global Fund for 2020 to 2022
18 October 2019. Related: Treatment access.
Global Fund raises US$14 billion for 2020 to 2022
18 October 2019. Related: Treatment access.
NHS England best practice in HIV prescribing and multidisciplinary teams
18 October 2019. Related: Guidelines.
US approves F/TAF for PrEP (Descovy): indication excludes risk from receptive vaginal sex
18 October 2019. Related: HIV prevention and transmission.
Science journal retracts article linking CCR5 deletion to reduced life expectancy
18 October 2019. Related: Basic science and immunology.
18 October 2019 vol 20 no 12
18 October 2019. Related: PDFs.
HTB 30 September 2019 online
30 September 2019. Related: Editorial.
10th IAS Conference on HIV Science (IAS 2019): final reports
30 September 2019. Related: Conference reports.
Low rates of pregnancy with three methods of contraception in the ECHO trial
30 September 2019. Related: Conference reports, Pregnancy.
Scotland approves dual therapy with dolutegravir/lamivudine (Dovato)
30 September 2019. Related: Antiretrovirals, Treatment access.
FDA expands indication for doravirine in the US as switch option
30 September 2019. Related: Antiretrovirals.
Greater weight gain with INSTI-based than non-INSTI-based ART among women in US cohort
30 September 2019. Related: Side effects.
WHO update PrEP guidelines to include event-based dosing
30 September 2019. Related: Guidelines, HIV prevention and transmission.
UK issue joint guidelines on HIV discrimination in tattoo and beauty salons
30 September 2019. Related: Guidelines, HIV prevention and transmission.
UK HIV organisations call for urgent review of crisis in sexual health funding
30 September 2019. Related: Treatment access, Other news.
UK is one of four EU countries to lose measles elimination status
30 September 2019. Related: Other news.
Women and HIV research: free educational webcasts
30 September 2019. Related: On the web.
30 September 2019 vol 20 no 11
30 September 2019. Related: PDFs.
Other pregnancy studies IAS 2019
17 September 2019. Related: Conference reports, Pregnancy.
HTB 23 August 2019 online: second reports from IAS 2019
23 August 2019. Related: Editorial.
10th IAS Conference on HIV Science (IAS 2019) in Mexico City
23 August 2019. Related: Conference reports.